MAOIs work by blocking monoamine oxidase, an enzyme that breaks down three key brain chemicals: serotonin, dopamine, and norepinephrine. When this enzyme is blocked, those neurotransmitters accumulate in the spaces between nerve cells, strengthening the signals associated with mood, motivation, and alertness. It’s a straightforward concept, but the details of how it happens, why dietary restrictions exist, and how different types of MAOIs behave all matter for understanding these powerful medications.
What Monoamine Oxidase Normally Does
Your brain constantly produces serotonin, dopamine, and norepinephrine to regulate mood, focus, pleasure, and stress responses. But it also needs a way to clear these chemicals out once they’ve done their job. That’s where monoamine oxidase comes in. This enzyme sits inside nerve cells and chemically dismantles neurotransmitters through a process called oxidative deamination. In simple terms, MAO strips hydrogen atoms off the neurotransmitter molecule, breaking it down into inactive byproducts that the body can dispose of.
This cleanup system runs continuously. Without it, neurotransmitter levels would climb unchecked. In people with depression, the theory is that this cleanup process works too efficiently, or neurotransmitter production is too low, leaving too little serotonin, dopamine, or norepinephrine available for nerve signaling. MAOIs tip the balance back by disabling the cleanup crew.
Two Versions of the Enzyme
The body produces two forms of monoamine oxidase, called MAO-A and MAO-B, and each has different preferences. MAO-A favors serotonin as its primary target, while MAO-B has a stronger preference for a compound called phenylethylamine and plays a larger role in dopamine breakdown. Both forms share about 70% of their molecular structure, and the difference in what they target comes down to a single amino acid at the binding site.
This distinction has major clinical consequences. MAO-A is concentrated in the gut, heart, and certain brain neurons that produce norepinephrine and dopamine. MAO-B is the dominant form in the brain overall, accounting for roughly 80% of total brain MAO activity, and is concentrated in the support cells (glial cells) surrounding neurons. Drugs that selectively target one form over the other can produce very different therapeutic effects and side-effect profiles.
Irreversible vs. Reversible Inhibitors
The oldest and most studied MAOIs, including phenelzine and tranylcypromine, are irreversible inhibitors. They work by forming a permanent chemical bond with the enzyme’s active site. Specifically, the drug gets processed by MAO like a normal substrate, but the resulting molecule locks onto a component of the enzyme called the FAD cofactor and never lets go. The enzyme is permanently disabled.
This matters because your body can’t simply “unbind” the drug. Instead, it has to manufacture entirely new MAO enzymes to replace the inactivated ones. In the brain, the half-life of MAO-B is 30 to 40 days, meaning the effects of irreversible inhibitors persist long after the drug itself has left your bloodstream. This is why washout periods are required when switching medications.
Reversible inhibitors take a different approach. They bind to the enzyme temporarily and can be displaced by competing molecules. If tyramine or another amine floods in, it can push the reversible inhibitor off the enzyme, allowing MAO to resume its normal function. This makes reversible inhibitors inherently safer in terms of food and drug interactions, though they may be somewhat less potent for treatment-resistant depression.
Why Certain Foods Become Dangerous
The most well-known concern with MAOIs is the so-called “cheese effect,” and it comes down to a compound called tyramine. Tyramine is found naturally in aged, fermented, or cured foods: aged cheeses, cured meats, sauerkraut, soy sauce, and some wines. Under normal circumstances, MAO-A in your gut breaks down dietary tyramine before it reaches your bloodstream. You eat aged cheddar, your gut enzymes neutralize the tyramine, and nothing happens.
When MAO-A is blocked by an irreversible inhibitor, tyramine passes through the gut intact and enters the bloodstream. Once there, it gets taken up by nerve terminals through the same transporter that handles norepinephrine. Inside the nerve terminal, tyramine forces massive quantities of stored norepinephrine, epinephrine, and dopamine out into circulation. The sudden surge of norepinephrine causes blood vessels to constrict, heart rate to spike, and blood pressure to climb rapidly. Severe elevations above 180/120 mm Hg can cause a hypertensive emergency with risk of stroke, organ damage, or death.
For most people on MAOIs, reaching dangerously high blood pressure would require ingesting more than 40 milligrams of tyramine in a single meal. That’s a meaningful amount, but not hard to reach with the wrong food choices. A large serving of well-aged cheese or a combination of high-tyramine foods could get there. This is why patients on non-selective, irreversible MAOIs follow a low-tyramine diet.
The Transdermal Patch Workaround
One of the more clever developments in MAOI therapy is the selegiline transdermal patch. Selegiline delivered through the skin at a dose of 6 mg over 24 hours reaches the brain directly through the bloodstream, bypassing the gut. This means it inhibits MAO in the brain (where you want the antidepressant effect) without significantly blocking MAO-A in the intestinal wall (where you need tyramine to be broken down). At this dose, no dietary tyramine restrictions are required. Higher doses of the patch do reintroduce the need for dietary caution, but the lowest effective dose offers the antidepressant benefits of an MAOI with a much more practical daily routine.
MAO-B Inhibitors in Parkinson’s Disease
Selective MAO-B inhibitors have carved out an entirely separate role in treating Parkinson’s disease. Parkinson’s involves the progressive loss of dopamine-producing neurons in the brain. By blocking MAO-B, which handles a large share of dopamine breakdown in the brain, these drugs preserve whatever dopamine the remaining neurons produce. This boosts dopamine signaling at the synapse without requiring the body to make more of it.
Newer MAO-B inhibitors like safinamide are remarkably selective, showing 5,000 times greater affinity for MAO-B over MAO-A. Older drugs like selegiline (in oral form, at low doses used for Parkinson’s) are about 127 times more selective. This selectivity is important because it means these drugs don’t significantly affect serotonin or norepinephrine metabolism at therapeutic doses, reducing the risk of food interactions and blood pressure problems.
Drug Interactions and Washout Periods
The interaction between MAOIs and other medications that raise serotonin levels is potentially life-threatening. Combining an MAOI with an SSRI, SNRI, or certain pain medications can trigger serotonin syndrome, a condition marked by dangerously high serotonin activity that causes agitation, high fever, muscle rigidity, and in severe cases, organ failure.
Because of this risk, strict washout timelines apply when switching medications. If you’re stopping an SSRI or SNRI before starting an MAOI, the standard washout period is at least two weeks. Fluoxetine is the exception: because it and its active byproduct linger in the body far longer than other SSRIs, a five-week washout is required. Going the other direction, stopping an MAOI before starting a different antidepressant requires a 14-day drug-free period to ensure the irreversible inhibitor’s effects have diminished enough for new MAO enzymes to take over.
Switching between two MAOIs that share the same mechanism can sometimes be done with a shorter gap of one to eight days, but this is managed carefully on a case-by-case basis.
How Effective MAOIs Actually Are
Despite their reputation as difficult medications, MAOIs have response rates above 50%, matching or exceeding older tricyclic antidepressants. They remain particularly valued for treatment-resistant depression and atypical depression (characterized by oversleeping, overeating, heavy feelings in the limbs, and sensitivity to rejection). The reason they’re typically used as second- or third-line treatments isn’t effectiveness. It’s the dietary restrictions, drug interaction risks, and the need for careful patient education that keep them from being prescribed first.
For the right patient, especially someone who hasn’t responded to SSRIs, SNRIs, or other first-line options, MAOIs can be transformative. The biochemistry is simple: more serotonin, dopamine, and norepinephrine available at the synapse, for longer. The practical management just requires more attention than most modern antidepressants demand.